Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab plus eltrombopag versus placebo plus eltrombopag in primary immune thrombocytopenia
jRCT2031220623Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ianalumab and eltrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Novartis. Primary endpoint: Time from randomization until treatment failure. Started Aug 2023; status: active, not recruiting.
02
Drugs
ianalumabeltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2031220623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220623.